|
NovaXS Biotech wins Pad-13 Pitch Competition and is voted Audience Favorite
|
|
|
Last Thursday, NovaXS Biotech won SkyDeck’s Pad-13 Pitch Competition, where eleven Pad-13 companies showcased their products to SkyDeck advisors, mentors, alumni and investors. Alina Su, the founder and CEO of NovaXS, was also voted Audience Favorite.
Faxx, a social media startup focused on anonymous messaging, founded by three Berkeley M.E.T. students won 2nd place for the Judges’ Award. Reveel, a Web3 platform for payment tracking for accounting for creators, founded by Haas alumni Adrien Stern, won 2nd place for the Audience Favorite Award.
|
|
|
|
Alina Su, CEO of NovaXS, is currently finishing
her Ph.D at Harvard Medical School.
|
|
SkyDeck Fund promotes Brian Bordley to Partner
|
|
|
Berkeley SkyDeck Fund has announced that it has promoted Brian Bordley to Partner. "Over the past four years since I launched the SkyDeck Fund, Brian Bordley has played an instrumental role in helping to identify some of our best startups that have come through SkyDeck and in working with them. His promotion to partner is well deserved," said SkyDeck Fund Managing Partner Chon Tang.
Brian joined Berkeley SkyDeck Fund four years ago during the first funded cohort. Before joining Berkeley SkyDeck Fund, Brian spent several years in startup operations, including time as a founder in SkyDeck in 2015. In his new role, Brian will continue to support SkyDeck's Cohort and Alumni Founders.
|
|
The SkyDeck Fund is hiring!
|
|
|
The Berkeley SkyDeck Fund is looking for a platform associate/analyst to join its team. The ideal candidate will work closely with the fund’s partners to ensure the fund is properly supporting its portfolio companies, properly maintain accurate financials/updates of its 150+ startups, grow its network of collaborative investors (VC + Angels), engage deal flow partners, and throw great events. Interested candidates, apply here.
|
|
|
Oncocross
Oncocross has initiated a clinical trial for an AI-developed drug for sarcopenia, a disease characterized by progressive loss of skeletal muscle mass and strength, thereby deteriorating normal physical function. Oncocross obtained Australia’s Therapeutic Goods Administration approval on phase I IND application for OC514 on February 14, 2022 and began a clinical trial with healthy adults in Australia. “OC514 has a significant meaning for us since it is one of the first AI-driven drug candidates for sarcopenia that is going into clinical trials globally,” said Dr. Yi Rang Kim, the company's CEO. Oncocross’ clinical trial was featured in Bloomberg Magazine.
|
|
|
Geopogo
Geopogo AR (Fall '19 and Spring '20 Pad-13) has been granted its third Metaverse/AR patent from the US Patent and Trademark Office. The patent for "rapid design and visualization of three-dimensional designs with multi-user input" is vital for Geopogo’s core subscription product, instantly converting industry-standard design files, such as Autodesk Revit, into full-size, interactive AR models.
|
|
|
|
YouVue
YouVue (Batch 12 Pad-13) is selected among the first 50 finalists in the Mission for the Future Challenge by LG NOVA, a global competition for companies that represent new developments in areas of health, renewable energy, mobility, improvements for communities, metaverse, and innovation. Selected companies, including YouVue, will partner with LG to build their businesses. The collaboration will enable YouVue to accelerate its mission of making immersive media ready for mass consumption.
|
|
|
|
|
|
|
|
